A new Yale study has found a promising target for treating the brain fog that can follow COVID-19 and offers new insight into ...

Holstege was supported by ABOARD, a public-private partnership receiving funding from ZonMw and Health Holland, Topsector Life Sciences and Health, the Hans und Ilse Breuer Stiftung, the Horstingstuit ...

An artificial intelligence (AI) model developed by Mayo Clinic and Ultromics, Ltd., an AI echocardiography company based in ...

An increased amyloid-β load is not a benign result of aging; it is associated with lower cognitive performance and poor ...

In people with normal cognition, depressive symptoms and amyloid pathology were not associated with each other (OR 1.13, 95% CI 0.90-1.40, P=0.29), reported Julie Oomens, PhD, of Maastricht ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat ...